NEW YORK and HERZLIYA PITUACH,
Israel, Dec. 1, 2014 /PRNewswire/ -- A renowned
speaker board, including senior executives from Genzyme, GSK,
Takeda, AZ, BMS, Roche, Pfizer, Biogen Idec, among others, and the
publishers of In Vivo, Startup and The Pink Sheet announced that
bertilimumab has been chosen as one of the top
autoimmune/anti-inflammatory projects to watch. This award
represents a significant industry honor. Many of the past
award winners include those who have partnered successfully such as
Trophos, BiPar, Myogen, Sirtris and Kosan.
Dr. Daniel Teper, CEO of IMMUNE
Pharmaceuticals (NASDAQ: IMNP) comments: "We believe that
bertilimumab has the potential to be the game-changing for the
treatment of several auto-immune diseases. Patient selection based
on eotaxin-1 level supports personalized medicine approach allowing
physicians to select the right drug for the right patient."
Products selected as one of the top autoimmune/anti-inflammatory
projects to watch have met rigorous criteria, including potential
large market, large unmet need, with increasing opportunity,
history of the molecule and drug, strong science, strong company,
diversity of indications, potential for new opportunities beyond
the initial indications, and multi-level partnering
opportunities.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to
treatment, developing novel, highly targeted antibody therapeutics
to improve the lives of patients with inflammatory diseases and
cancer. The Company's lead product candidate, bertilimumab,
is in clinical development for moderate to severe ulcerative
colitis and Crohn's disease as well as bullous pemphigoid, an
orphan auto-immune dermatological condition. Immune licensed
worldwide rights for systemic indications of bertilimumab from iCo
Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all
ophthalmic indications. iCo originally licensed the exclusive
world-wide rights to bertilimumab in 2006 from MedImmune, the
Global Research and Development Arm of AstraZeneca. Immune's
pipeline also includes NanomAbs®, antibody nanoparticle conjugates,
for the targeted delivery of chemotherapeutics, and AmiKet™, a
Neuropathic Pain drug candidate ready for Phase III. AmiKet has
received Orphan Drug Designation for Post Herpetic Neuralgia.
For more information, visit Immune's website at
www.immunepharmaceuticals.com, the content of which is not a part
of this press release.
Erik Penser Bankaktiebolag is engaged as Immune's Certified
Adviser on NASDAQ OMX First North Premier.
Forward-Looking Statements
This news release and any oral statements made with respect to
the information contained in this news release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of
those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency,
goals, targets, future development and are otherwise not statements
of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause
actual results or developments to differ materially include, but
not limited to: the risks associated with the adequacy of our
existing cash resources and our ability to continue as a going
concern; the risks associated with our ability to continue to meet
our obligations under our existing debt agreements; the risk that
clinical trials for bertilimumab or AmiKet™ will not be successful;
the risk that bertilimumab, AmiKet™ or compounds arising from our
NanomAb® program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able
to find a partner to help conduct the Phase III trials for AmiKet™
on attractive terms, on a timely basis or at all; the risk that our
other product candidates that appeared promising in early research
and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later-stage clinical trials; the risk that we will
not obtain approval to market any of our product candidates; the
risks associated with dependence upon key personnel; the risks
associated with reliance on collaborative partners and others for
further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly
competitive nature of our business; risks associated with
litigation; and risks associated with our ability to protect our
intellectual property. These factors and other material risks are
more fully discussed in our periodic reports, including our reports
on Forms 8-K, 10-Q and 10-K and other filings with the U.S.
Securities and Exchange Commission. You are urged to carefully
review and consider the disclosures found in our filings which are
available at www.sec.gov or at www.immunepharmaceuticals.com. You
are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to
inaccurate assumptions, unknown risks or uncertainties or other
risk factors. We expressly disclaim any obligation to publicly
update any forward looking statements contained herein, whether as
a result of new information, future events or otherwise, except as
required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bertilimumab-chosen-as-a-top-autoimmuneanti-inflammatory-projects-to-watch-300002306.html
SOURCE Immune Pharmaceuticals Inc.